Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

B Cell Activation and Differentiation

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Longitudinal plasma neurofilament light chain and patient-reported outcomes as complementary markers of vincristine-associated peripheral neuropathy in adults with lymphoma: a cohort study.

medRxiv : the preprint server for health sciences·2026

Same author

Identification of an optimal absolute lymphocyte count at leukapheresis in patients with lymphoma treated with CART.

Blood immunology & cellular therapy·2026

Same author

Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma.

Blood cancer journal·2026

Same author

Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

Blood advances·2026

Same author

Cardiovascular adverse events associated with bispecific antibodies in relapsed or refractory B-cell non-Hodgkin lymphomas.

Journal of hematology & oncology·2026

Same author

Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real-world analysis from 20 US centers.

HemaSphere·2026

Search research articles

Related Experiment Video

Updated: Sep 27, 2025

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Identifying aggressive subsets within diffuse large B-cell lymphoma: implications for treatment approach.

Timothy J Voorhees¹, Narendranath Epperla¹

¹James Comprehensive Cancer Center, Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, Ohio, USA.

Expert Review of Anticancer Therapy

|April 7, 2022

Summary

Identifying high-risk diffuse large B-cell lymphoma (DLBCL) is crucial for effective treatment. Combining clinical, pathological, and molecular data offers improved strategies for these challenging cases.

Keywords:

High-risk DLBCL clinical risk molecular subtypes novel therapy targeted therapy

More Related Videos

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Related Experiment Videos

Last Updated: Sep 27, 2025

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Area of Science:

Hematology
Oncology
Genomics

Background:

Diffuse large B-cell lymphoma (DLBCL) presents a challenge for a subset of patients despite chemoimmunotherapy.
Accurate identification of high-risk DLBCL is essential for developing targeted therapeutic strategies.

Purpose of the Study:

To review current methods for risk stratification in DLBCL.
To explore the integration of clinical, pathological, and molecular data for improved patient outcomes.

Main Methods:

Discussion of established clinical and pathological risk stratification models.
Analysis of molecular subtypes derived from whole exome sequencing.
Review of current therapeutic approaches and future directions.

Main Results:

Traditional risk models lack granularity for individual patient pathology and treatment response.
Molecular subtypes possess independent prognostic value in DLBCL.
Targeting specific DLBCL subtypes with novel therapies has shown modest benefits.

Conclusions:

Integrating clinical, pathological, and molecular data is key to enhancing the identification of aggressive DLBCL subsets.
Future research should focus on novel therapies and clinical trial designs for high-risk DLBCL populations.